Multimodality Imaging for Evaluating Response to Neoadjuvant Chemotherapy in Breast Cancer.
OBJECTIVE
Neoadjuvant chemotherapy is becoming the standard of care for patients with locally advanced breast cancer. Conventional imaging modalities used for the assessment of tumor response to neoadjuvant chemotherapy rely on changes in size or morphologic characteristics and, therefore, are inherently limited.


CONCLUSIONS
Functional imaging technologies evaluate vascular, metabolic, biochemical, and molecular changes in cancer cells and have a unique ability to detect specific biologic tumor markers, assess therapeutic targets, predict early response to neoadjuvant chemotherapy, and guide individualized cancer therapy.
1 Department of Diagnostic Radiology, Unit 1473, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030-4009.
Gaiane M
GM
Rauch
2 Department of Diagnostic Radiology, Unit 1350, The University of Texas MD Anderson Cancer Center, Houston, TX.
Beatriz Elena
BE
Adrada
3 Department of Breast Surgical Oncology, Unit 1434, The University of Texas MD Anderson Cancer Center, Houston, TX.
Henry Mark
HM
Kuerer
3 Department of Breast Surgical Oncology, Unit 1434, The University of Texas MD Anderson Cancer Center, Houston, TX.
Raquel F D
RF
van la Parra
2 Department of Diagnostic Radiology, Unit 1350, The University of Texas MD Anderson Cancer Center, Houston, TX.
Jessica W T
JW
Leung
4 Department of Diagnostic Radiology, Unit 1459, The University of Texas MD Anderson Cancer Center, Houston, TX.
Wei Tse
WT
Yang
D000970:Antineoplastic Agents / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant / Q000379:methods; D016903:Drug Monitoring / Q000379:methods*; D005260:Female; D006801:Humans; D008327:Mammography / Q000379:methods*; D064847:Multimodal Imaging / Q000379:methods*; D020360:Neoadjuvant Therapy / Q000379:methods*; D017063:Outcome Assessment, Health Care / Q000379:methods
D000970:Antineoplastic Agents
breast MRI; breast PET; breast cancer; molecular breast imaging; neoadjuvant chemotherapy